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Abstract The preponderance of large-scale healthcare databases provide abundant opportunities for com-
parative effectiveness research. Evidence necessary to making informed treatment decisions often relies on
comparing effectiveness of multiple treatment options on outcomes of interest observed in a small number of
individuals. Causal inference with multiple treatments and rare outcomes is a subject that has been treated
sparingly in the literature. This paper designs three sets of simulations, representative of the structure of our
healthcare database study, and propose causal analysis strategies for such settings. We investigate and com-
pare the operating characteristics of three types of methods and their variants: Bayesian Additive Regression
Trees (BART), regression adjustment on multivariate spline of generalized propensity scores (RAMS) and in-
verse probability of treatment weighting (IPTW) with multinomial logistic regression or generalized boosted
models. Our results suggest that BART and RAMS provide lower bias and mean squared error, and the
widely used IPTW methods deliver unfavorable operating characteristics. We illustrate the methods using a
case study evaluating the comparative effectiveness of robotic-assisted surgery, video-assisted thoracoscopic
surgery and open thoracotomy for treating non-small cell lung cancer.
Keywords Causal inference · Multiple treatments · Rare outcomes · Generalized propensity scores ·
Machine learning
1 Introduction
1.1 A comparative effectiveness study
Robotic-assisted surgery (RAS), a minimally invasive technology that uses robotic system to enhance instru-
ment maneuverability and visualization, was introduced in 2002 to treat resectable non-small cell lung cancer
(NSCLC) (Melfi et al., 2002). This technology enables surgeons to perform intricate maneuvers with greater
precision (Veluswamy et al., 2019). There are no randomized controlled trials (RCTs) that have been con-
ducted to compare the effectiveness of RAS with commonly used surgical approaches. Current comparative
effectiveness studies have been relying on healthcare databases.
Several studies reported shorter length of stay, reduced pain, less postoperative bleeding and lower rate
of myocardial infarction among NSCLC patients who were treated with RAS compared to those who were
operated via open thoracotomy (OT) (Veronesi et al., 2010; Cerfolio et al., 2011; Oh et al., 2017), and similar
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survival compared to those who received video-assisted thoracoscopic surgery (VATS), another minimally
invasive technology (Farivar et al., 2014). With more evidence supporting its feasibility and safety, RAS
has been rapidly adopted since 2008 (Novellis et al., 2017). The lack of randomization however contributed
to diverging results. For example, Veluswamy et al. (2019) showed that RAS led to similar post-operative
cardiovascular complication rate as VATS and OT, and recommended that comparative effectiveness of RAS
should be further evaluated prior to widespread adoption.
Previous comparative research of theses surgical approaches is limited with respect to the statistical anal-
ysis approach. Existing studies primarily focused on pairwise comparison between two surgical approaches for
patients who are eligible for the specific pair of surgical procedures (Cajipe et al., 2012; Farivar et al., 2014).
Findings from these studies, in general, cannot inform the optimal surgical method for the entire population
who are eligible for all three surgical procedures (Lopez and Gutman, 2017). Veluswamy et al. (2019) used
a matched study cohort that was much smaller than the sample population, limiting the generalizability of
their study results.
1.2 Research gaps and objectives
The healthcare databases for this comparative question pose additional statistical challenges. One important
outcome for assessing the effectiveness of different surgical management methods is postoperative morbidity
(e.g., extrapulmonary infection, cardiovascular complication, etc.). However, only a small fraction of patients
may have these complications after surgery (Veluswamy et al., 2019). For example, less than 3% of NSCLC
patients who underwent surgeries experienced cardiovascular complication, and less than 2% had reoperation.
The small number of outcome events in these surgical groups implies limited information on the comparison
of the surgical approaches. As such, we need to compare a large amount of patients receiving different
treatment regimens with respect to the risk of the health event of interest, while adjusting for many potential
confounders. This is particularly challenging with rare outcomes because the great majority of patients
contribute no information to explaining the variability attributable to the differential treatment regimens
in the health events. Other examples of rare outcomes include studies of rare disease or rare adverse safety
event or new treatment. Despite the challenge on analytic efficiency posed by rare outcomes, research on the
performance of causal inference techniques in this context is sparse with the exception of Cepeda et al. (2003)
and Franklin et al. (2017), which applied and compared different propensity score methods in the context
of rare outcomes and a binary treatment. Cepeda et al. (2003) conducted simulation studies to compare
logistic regression with propensity score methods when the number of events is low relative to the number of
confounders, and found that the propensity score methods had more empirical power than logistic regression.
Franklin et al. (2017) further described and compared a multitude of propensity score-based approaches in
healthcare database studies with rare outcomes in the context of binary treatment. Their simulation study
concluded that regression adjustment on propensity score using one nonlinear spline (RAONS) performed
best with respect to bias and RMSE in the absence of treatment heterogeneity.
Causal inference techniques have traditionally focused on binary treatment. There has been growing
literature developing regression and propensity score-based techniques with multiple treatments in recent
years. These methods were developed with continuous outcomes in mind and were less studied for binary
outcomes. Lopez and Gutman (2017) provided a comprehensive review of current methods for multiple
treatments. Hu et al. (2020) explicated use of methods appropriate for multiple treatments in the context
of binary outcomes (with prevalence rate between 10% to 75%) and presented empirical evidence about
the performances of several propensity score- and machine learning-based methods in a variety of complex
causal inference settings, considering sample size, ratio of units, non-linearity and non-additivity of both the
treatment assignment and outcome generating mechanisms and levels of covariate overlap. Sets of simulations
in Hu et al. (2020) suggest that Bayesian Additive Regression Trees (BART) – a nonparametric modeling
technique – provides best performance on the bases of better bias reduction, smaller root mean squared
error (RMSE), more consistent 95% uncertainty coverage and better large-sample convergence property,
compared to inverse probability of treatment weighting (IPTW)(Feng et al., 2012), regression adjustment
(RA) (Linden et al., 2016), generalized boosted models (GBM) (McCaffrey et al., 2013), vector matching
(Lopez and Gutman, 2017), targeted maximum likelihood estimation (TMLE), (Rose and Normand, 2019)
and IPTW with super learner (Van der Laan et al., 2007).
Estimation of causal effects of multiple treatments in healthcare database studies with rare outcomes 3
To our knowledge, there is no literature comparing causal inference approaches in the context of both
rare outcomes and multiple treatments.To fill in research gaps in causal inference literature in the setting of
multiple treatments and rare outcomes, we first select the top performer in each component of the setting,
i.e.,BART for the multiple treatment setting and RAONS for the binary treatment and rare outcomes
setting, and then extend the two methods in the context of multiple treatments and binary outcomes. We
propose a new strategy, regression adjustment on multivariate spline of the generalized propensity score
(GPS) (RAMS), which extends RAONS to accommodate multiple treatments by using a nonlinear spline
model for the outcome that is additive in the treatment and multivariate spline function of the GPS. In
addition, we include IPTW as a comparison method because it is widely used in the causal analysis of
multiple treatments. We further generate simulation scenarios that are uniquely representative of studies
constructed from large scale healthcare databases and provide empirical evidence regarding the comparison
of the three types of methods and their varied versions via extensive simulations. Our results suggest BART
consistently provides the best performance corresponding to bias and RMSE across all scenarios considered,
RAMS has similar performance under certain settings with the advantage of computational efficiency, and
the widely used IPTW methods deliver poor operating characteristics in all conditions.
This paper is organized as follows: the remainder of Section 1 provides additional background on the
healthcare database study. Section 2 introduces the potential outcomes framework for multiple treatments
and the methods for estimating causal effects with multiple treatments. Section 3 presents the design and
results of the Monte Carlo simulation. Section 4 describes the empirical data analysis. Conclusions and
discussions are provided in Section 5.
1.3 Data source: SEER-Medicare linkage
To demonstrate the methods, we conduct a case study constructed from the latest SEER-Medicare linkage
to compare the effects of RAS, VATS and OT among early stage NSCLC patients. The data set includes a
total of 11980 patients above 65 years of age with stage I-IIIA NSCLC, diagnosed between 2008 (first year
patients in the registry underwent robotic-assisted surgery) and 2013, and underwent one of the three surgical
procedures. Among these patients, 396 (3.3%), 6582 (54.9%) and 5002 (41.8%) received RAS, VATS and OT,
respectively. The data set contains patient-level pre-treatment information on socio-demographics (including
age, gender, marital status, race, income level), year of diagnosis, comorbidities, tumor characteristics and
stage (including cancer stage, tumor size, tumor site, histology), and preoperative evaluation (including
positron emission tomography [PET] scan, chest computer tomography or mediastinoscopy). We use the
postoperative morbidity as the outcome, which is defined as the presence of complications within 30 days
of surgery or during the hospitalization in which surgery was performed (Veluswamy et al., 2019). In this
study, four types of complications that are rare from Medicare claims are used: 1) extrapulmonary infections;
2) cardiovascular complications; 3) thromboembolic events; 4) reoperations. Table 1 summarizes baseline
characteristics and postoperative complications for the overall population and each surgical group.
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Table 1: Baseline characteristics of subjects receiving three surgical procedures in the SEER-Medicare dataset. SD: standard
deviation. OT: Open Thoracotomy. RAS: Robotic-Assisted Surgery. For statistical testing, regular ANOVA was used for conti-
nous variables. Chi-squared test was used for categorical variables. †: the number of events under 11 was masked according to
the CMS cell size suppression policy.
Overall VATS OT RAS p-value
Variables N = 11980 N = 6582 N = 5002 N = 396
Preoperative characteristics complications
Age (years), mean (SD) 74.2 (5.6) 73.9 (5.4) 74.5 (5.7) 74.3 (5.7) 0.077
Female, N (%) 6610 (55.2) 3446 (52.4) 2941 (58.8) 223 (56.3) 0.011
Married, N (%) 6782 (56.6) 3753 (57.0) 2802 (56.0) 227 (57.3) 0.537
Race, N (%)
White 10383 (86.7) 5694 (86.5) 4369 (87.3) 320 (80.8) 0.056
Black 633 (5.3) 364 (5.5) 248 (5.0) 21 (5.3) 0.395
Hispanic 372 (3.1) 218 (3.3) 139 (2.8) 15 (3.8) 0.190
Other 592 (4.9) 306 (4.6) 246 (4.9) 40 (10.1) <0.001
Median household annual income, N (%)
1st quartile 3238 (27.0) 2132 (32.4) 1009 (20.2) 97 (24.5) <0.001
2nd quartile 3010 (25.1) 1729 (26.3) 1193 (23.9) 88 (22.2) 0.042
3rd quartile 2586 (21.6) 1345 (20.4) 1143 (22.9) 98 (24.7) 0.022
4th quartile 3146 (26.3) 1376 (20.9) 1657 (33.1) 113 (28.5) <0.001
Charlson comorbidity score, N (%)
0− 1 4127 (34.4) 2163 (32.9) 1810 (36.2) 154 (38.9) 0.005
1− 2 3436 (28.7) 1944 (29.5) 1379 (27.6) 113 (28.5) 0.068
> 2 4417 (36.9) 2475 (37.6) 1813 (36.2) 129 (32.6) 0.064
Year of diagnosis, N (%)
2008-2011 8181 (68.3) 4842 (73.6) 3207 (64.1) 132 (33.3) <0.001
2012 1851 (15.5) 899 (13.7) 821 (16.4) 131 (33.1) <0.001
2013 1948 (16.3) 841 (12.8) 974 (19.5) 133 (33.6) <0.001
Cancer stage, N (%)
Stage I 8374 (69.9) 4195 (63.7) 3884 (77.6) 295 (74.5) <0.001
Stage II 2276 (19.0) 1504 (22.9) 709 (14.2) 63 (15.9) <0.001
Stage IIIA 1330 (11.1) 883 (13.4) 409 (8.2) 38 (9.6) <0.001
Tumor size, in mm, N (%)
≤ 20 4359 (36.4) 1967 (29.9) 2232 (44.6) 160 (40.4) <0.001
21− 30 3182 (26.6) 1696 (25.8) 1388 (27.7) 98 (24.7) 0.041
31− 50 2900 (24.2) 1804 (27.4) 987 (19.7) 109 (27.5) <0.001
≥ 51 1539 (12.8) 1115 (16.9) 395 (7.9) 29 (7.3) <0.001
Histology, N (%)
Adenocarcinoma 7360 (61.4) 3757 (57.1) 3348 (66.9) 255 (64.4) <0.001
Squamous cell carcinoma 3439 (28.7) 2165 (32.9) 1167 (23.3) 107 (27.0) <0.001
Other histology 1181 (9.9) 660 (10.0) 487 (9.7) 34 (8.6) 0.601
Tumor site, N (%)
Upper lobe 6903 (57.6) 3829 (58.2) 2859 (57.2) 215 (54.3) 0.216
Middle lobe 670 (5.6) 308 (4.7) 335 (6.7) 27 (6.8) 0.103
Lower lobe 4056 (33.9) 2195 (33.3) 1720 (34.4) 141 (35.6) 0.381
Other site 351 (2.9) 250 (3.8) 88 (1.8) 13 (3.3) 0.078
PET scan, N (%) 8716 (72.8) 5004 (76.0) 3410 (68.2) 302 (76.3) <0.001
Chest computer tomography, N (%) 7936 (66.2) 4525 (68.7) 3148 (62.9) 263 (66.4) <0.001
Mediastinoscopy, N (%) 1197 (10.0) 715 (10.9) 420 (8.4) 62 (15.7) <0.001
Postoperative complications
Extrapulmonary infection 614 (5.1) 406 (3.9) 195 (6.2) 13 (3.3) <0.001
Cardiovascular complication† 270 (2.3) 160 (2.0) > 90 (> 2) < 11 (< 3) 0.281
Thromboembolic complication 559 (4.7) 302 (4.7) 236 (4.6) 21 (5.3) 0.786
Reoperation† 144 (1.2) 100 (0.8) < 50 (> 1) < 11 (< 2) 0.043
2 Methods
2.1 Potential outcomes framework for multiple treatments
Our notation is based on the potential outcomes framework, which was originally proposed by Neyman (1923)
in randomized experiments with randomization-based inference, and generalized to observational studies and
Bayesian analysis by Rubin (1974, 1977, 1978), commonly referred to as the Rubin Causal Model (Holland,
1986).
Suppose we are interested in evaluating the causal effect of a treatment or exposure W on outcome Y
for a sample of units, indexed by i = 1, . . . , N , drawn randomly from a target population. Each unit is
exposed to one of Z possible treatments; that is, Wi = w if individual i was observed under treatment w,
where w ∈ W = {1, 2, . . . , Z}. The number of units receiving treatment w is Nw and
∑Z
1 Nw = N . Let Yi
be the observed outcome of the ith unit given the assigned treatment, and {Yi(1), . . . , Yi(Z)} the potential
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outcomes for the ith unit under each possible treatment of W. Here we assume the stable unit treatment
value assumption (SUTVA) (Rubin, 1980), that is, no interference between units and no different versions
of a treatment. The observable outcome, Yi, for unit i can be written as
Yi =
∑
w∈{1,2,...,Z}
Yi(w)I(Wi = w), (1)
where I(·) is an indicator function. Known as the fundamental problem of causal inference, for each unit, at
most one of the potential outcomes is observed (the one corresponding to the treatment to which the unit is
exposed), and all other potential outcomes are missing (Holland, 1986).
Causal effects are summarized by estimands, which are functions of the unit-level potential outcomes on a
common of set of units (Rubin, 1974, 1978). Here we focus on a common estimand in comparative effectiveness
studies of binary outcomes, marginal risk difference(RD), in the multiple treatment setting. There are two
types of estimands, average treatment effect (ATE) and average treatment effect on the treated (ATT). We
focus on ATE in this paper as it is of great interest to generalize inference about the effectiveness of the
surgical approaches to the overall population. Implementation of all methods considered for ATT estimation
is straighforward. The ATE in terms of marginal RD in the sample for treatment k, l ∈ W is defined as
∆k,l =
N∑
i=1
Yi(k)−
N∑
i=1
Yi(l). (2)
In general, causal effects are not identifiable without further assumptions because only one of the po-
tential outcomes is observed for each unit. The key assumptions concern the assignment mechanism, or in
other words, how each unit received the treatment it actually received (Imbens and Rubin, 2015). The first
assumption is known as positivity or common support (overlap) assumption. More specifically,
0 < p(Wi|Yi(1), . . . , Yi(Z),Xi) < 1, ∀ w ∈ {1, . . . , Z},
where Xi is a vector of pre-treatment covariates. We further assume that, given the pre-treatment covariates,
Xi, the assignment mechanism does not depend on the potential outcomes, so that it is unconfounded
(Imbens and Rubin, 2015):
p(Wi|Yi(1), . . . , Yi(Z),Xi) = p(Wi|Xi), ∀ w ∈ {1, . . . , Z}. (3)
This assumption implies that the set of observed pre-treatment covariates, Xi, is sufficiently rich such that it
includes all variables directly influencing both Wi and Yi; in other words, there is no unmeasured confounding.
The probability in equation 3 is referred to as the GPS. For each unit, there is a vector of propensity scores
corresponding to each treatment, R(Xi) = (r(1,Xi), . . . , r(Z,Xi)), where r(w,Xi) = p(Wi = w|Xi), for
w ∈ W.
We also define the response surface as follows,
f(w,Xi) ≡ E[Yi(w)|Xi], ∀ w ∈ {1, . . . , Z}. (4)
Under the assumption of unconfoundedness and common support, the response surface for any w can be eval-
uated by the mean function of the observed outcomes conditional on treatment and pre-treatment covariates
Xi,
f(w,Xi) = E[Yi(w)|W = w,Xi] = E[Yi|W = w,Xi], (5)
2.2 Overview of methods considered for rare outcomes and multiple treatments
2.2.1 Inverse probability of treatment weighting
A widely used method to estimate causal effects with multiple treatments is the inverse probability of
treatment weighting (IPTW) (Rosenbaum, 1987; Robins et al., 2000). The concept of IPTW was originally
introduced by Horvitz and Thompson (1952) in survey research to adjust for imbalances in sampling pools.
Weighting methods have been extended to estimate causal effect of a binary treatment in observational
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studies, and recently reformulated to accommodate multiple treatments (Imbens, 2000; Feng et al., 2012;
McCaffrey et al., 2013). The weighting estimator of ∆k,l is written as follows:
∆̂iptwk,l =
∑N
i=1 YiI(Wi = k)/rˆ(k,Xi)∑N
i=1 YiI(Wi = l)/rˆ(l,Xi)
, (6)
where rˆ(w,Xi) is the estimated GPS, for w ∈ W. In practice, the GPS is often estimated from multinomial
logistic regression. A challenge of the IPTW method is that treated units with the estimated GPS that are
close to zero would result in extreme weights, which lead to unstable causal estimates with large sample
variances (Little, 1988; Kang et al., 2007). This issue is more likely as the number of treatments increases, as
treatment assignment probabilities for some treatment groups may become quite small (Lopez and Gutman,
2017). One remedy is weight trimming, or weight truncation, (Cole and Herna´n, 2008; Lee et al., 2011), by
which extreme weights that fall outside a specified range limit of the weight distribution are set to the range
limit. The limit is often based on percentiles of the weight distribution (e.g., the 5th and 95th percentiles).
An alternative method to estimating the GPS is the generalized boosted models (GBM) (Friedman, 2002;
McCaffrey et al., 2013). GBM is a machine learning technique and has been utilized in the binary treatment
setting to flexibly estimate complex and nonlinear relationship between treatment assignment and pre-
treatment covariates without overfitting the data (McCaffrey et al., 2004). GBM has an iterative estimation
procedure that can be tuned to find the propensity score model producing the best pre-treatment covariate
balance between treatment groups. Previous studies show that the use of machine learning techniques such
as GBM in propensity score estimation is able to alleviate extreme weights and improve the estimation of
causal effects (Lee et al., 2010; McCaffrey et al., 2013). However, the iterative algorithm of GBM can be
computationally intensive when the sample size or the number of pre-treatment covariates is large.
2.2.2 Bayesian Additive Regression Trees
Another causal inference approach is to directly model the response surface f(w,X). This method is also
known as regression adjustment (RA) (Rubin, 1973, 1979) or model-based imputation (Imbens and Rubin,
2015). Potential outcomes corresponding to treatment k and l for each unit are imputed, respectively, from the
regression model of f(w,X), and then averaged and contrasted to estimate the ATE effect ∆k,l. The critical
part of this method is the specification of the functional form of the regression model. Model misspecification
could lead to biased treatment effect estimates.
Given advances in Bayesian nonparametric models with highly flexible functional form, BART, has been
used to model the response surface f(w,X) (Chipman et al., 2007, 2010; Hill, 2011; Hu et al., 2020). BART
is a Bayesian ensemble method that models the conditional mean outcome by a sum of regression trees.
Chipman et al. (2010) has provided extensive evidence to demonstrate that BART has excellent predictive
performance and is well-suited to detecting nonlinearities and interactions with little parameter tuning
and coherent uncertainty estimation. Hill (2011) proposed the use of BART for causal inference with a
binary treatment. Hu et al. (2020) extended BART to estimate the causal effects of multiple treatments in
observational studies with a binary outcome. For a binary outcome, the BART model can be formulated to
the probit model setup
f(w,Xi) = E[Yi|Wi = w,Xi] = Φ
{ J∑
j=1
gj(w,Xi;Tj ,Mj)
}
, (7)
where Φ is the the standard normal c.d.f., each (Tj ,Mj) denotes a single subtree model in which Tj denotes
the regression tree and Mj is a set of parameter values associated with the terminal nodes of the jth regression
tree, gj(w,Xi;Tj ,Mj) represents the mean assigned to the node in the jth regression tree associated with
covariate value Xi and treatment level w, and the number of regression trees J is considered to be fixed
and known. The details of prior specification and Bayesian backfitting algorithm for posterior sampling can
be found in Chipman et al. (2010). A total of S Markov Chain Monte Carlo samples of model parameters,
(Tj ,Mj), are drawn from their posterior distribution. The missing potential outcomes are predicted for
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each unit and the relevant treatment level in each of S draw. The average treatment effect ∆k,l comparing
treatment group k and l can be estimated as follows:
∆̂bartk,l =
∑S
s=1
∑N
i=1 f
s(k,Xi)∑S
s=1
∑N
i=1 f
s(l,Xi)
=
∑S
s=1
∑N
i=1 Φ
{∑J
j=1 gj(k,Xi;T
s
j ,M
s
j )
}
∑S
s=1
∑N
i=1 Φ
{∑J
j=1 gj(l,Xi;T
s
j ,M
s
j )
} , (8)
where (T sj ,M
s
j ) are the sth draw from the posterior distribution of (Tj ,Mj). The point and interval estimates
of average treatment effects can be obtained using the summary of posterior samples.
Unlike the propensity score-based methods, BART is not equipped with a mechanism that prevents it
from extrapolating over the areas of the covariate space where common support does not exist. Hu et al.
(2020) proposed a strategy to identify a common support region for retaining inferential units, and provided
empirical evidence that the BART-specific discarding rule largely improved over BART based on bias re-
duction and RMSE by excluding units that fall outside the region of common support when there is lack of
covariate overlap. Their strategy discards units that have large variability in predicting potential outcomes.
Specifically, any unit i with Wi = w will be discarded if
s
fw′
i > maxj{sfwj },∀j : Wj = w, and w′ 6= w ∈ W, (9)
where sfwj and s
f ′w
j denote the standard deviation of the posterior distribution of the potential outcomes
under treatment W = w and W = w′, respectively, for a given unit j. When estimating the ATE, the
discarding rule in (9) is applied to each treatment group.
2.2.3 Regression Adjustment with Multivariate Spline of GPS
Regression adjustment with the PS is an alternative to the commonly used PS-based methods using weight-
ing, matching, and stratification (Hade and Lu, 2014; Vansteelandt and Daniel, 2014). This method involves
a regression model for the outcome with the treatment and PS being the independent variables. However, the
treatment effects estimated using this method may be biased when the regression model is misspecified, even
if the PS model is correct (Cangul et al., 2009; Vansteelandt and Daniel, 2014). One way to overcome this
problem is to allow for a flexible regression model to capture the nonlinear association between the outcome
and the PS via a spline function (e.g., penalized spline of the PS) (Gutman and Rubin, 2013; Hade and Lu,
2014; Vansteelandt and Daniel, 2014). Franklin et al. (2017) used expansive simulations to show that this
method performed best corresponding to bias and RMSE compared to a multitude of PS-based methods in
the context of rare outcome.
Building on the work by Franklin et al. (2017), we extend this method into the multiple treatment setting
using a multivariate spline of the GPS. More specifically, with a binary outcome, we assume a nonlinear
relationship between the outcome and the multivariate spline of the GPS as follows:
f(w,Xi) = E[Yi|Wi = w,Xi] = logit−1
{
βWi + h(R(Xi),γ)
}
, (10)
where h(·) is some spline function of the GPS indexed by γ and β = [β1, . . . , βZ ]T are regression coefficients
associated with the treatment Wi. The dimension of the spline function h(·) depends on the number of
treatments Z. For example, when Z = 3, h(·) is a bivariate spline function. We used the first two dimensions
of the GPSs to construct the spline function in our simulations and data analysis. An empirical sensitivity
analysis found the estimates of causal effects did not vary with the dimensions of the GPSs; see Table
S5 in the Supplemental Materials. The multivariate spline function can be specified using additive spline
bases, tensor products of spline bases or radial basis functions (Ruppert et al., 2003). To better capture
the correlation between the components of R(Xi) and facilitate easy-implementation of this method, we
consider a tensor product spline that can be implemented using the off-the-shelf statistical software packages
for h(·). The estimator of the ATE ∆k,l by this method is
∆̂ramsk,l =
∑N
i=1 f(k,Xi)∑N
i=1 f(l,Xi)
=
∑N
i=1 logit
−1
{
βˆkI(Wi = k) + h(R(Xi), γˆ)
}
∑N
i=1 logit
−1
{
βˆlI(Wi = l) + h(R(Xi), γˆ)
} . (11)
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In our simulations and data application, we also considered a variant of RAMS with trimmed GPSs to lessen
the impact of extreme GPSs.
3 Simulation studies
3.1 Simulation design
We conducted three sets of simulations to investigate and compare the operating characteristics of the meth-
ods described in Section 2.2. We based the design of our simulations on the structure of the SEER-Medicare
data described in Section 1.3. We assumed three treatment groups (Z = 3) throughout the simulations.
3.1.1 Simulation I: Ratio of units and sample size
In the first simulation, we considered a combination of two design factors: the ratio of units in the treatment
groups (n1 : n2 : n3) and the study sample size (i.e., the total number of units N = n1 + n2 + n3). We
considered three scenarios for the two factors: 1) n1 : n2 : n3 = 1 : 1 : 1 and N = 1500, 2) n1 : n2 : n3 =
1 : 4 : 3 and N = 4000 and 3) n1 : n2 : n3 = 1 : 10 : 8 and N = 9500 to respectively represent equal,
moderately unequal and highly unequal sample sizes across treatment groups. The third scenario of highly
unequal sample sizes represents the SEER-Medicare database study, in which RAS is the smallest treatment
group for it is a relatively new technology.
We considered a total of 10 confounders consisted of five continuous variables and five categorical variables.
We assumed that both the treatment assignment mechanism and the response surfaces are nonlinear models
of the confounders. Specifically, the treatment assignment followed a multinomial logistic regression model.
Assuming the third treatment group is the reference group, Wi ∼ Multinomial(N, p1, p2, p3) with
p(Wi = 1|Xi) = ex1i
1 + ex1i + ex2i
p(Wi = 2|Xi) = ex2i
1 + ex1i + ex2i
p(Wi = 3|Xi) = 1
1 + ex1i + ex2i
,
(12)
and
ex1i = exp(α1 +Xiξ
L
1 +Qiξ
NL
1 )
ex2i = exp(α2 +Xiξ
L
2 +Qiξ
NL
2 ),
where Qi denotes the nonlinear transformations and higher-order terms of the covariates in Xi, ξ
L
1 and ξ
L
2
are vectors of coefficients associated with Xi, and ξ
NL
1 and ξ
NL
2 are vectors of coefficients associated with
Qi. The intercepts α1 and α2 were specified to create the corresponding ratio of units in three treatment
groups in each scenario. We generated three sets of response surfaces as follows:
E[Y (w)|Xi] = logit−1{τw +XiηLw +QiηNLw }, w ∈ {1, 2, 3}, (13)
where regression coefficients (τw, η
L
w, and η
NL
w ) were chosen so that the outcome prevalence in the treatment
groups were similar as the rates of cardiovascular complication (2%–3%) observed in the SEER-Medicare
data. Details of model specification in Equation (12) and (13) appear in Table S1 of Supplementary Materials.
We compared the following nine methods in Simulation I: 1) IPTW with GPS estimated using multinomial
logistic regression (IPTW-MLR); 2) IPTW with GPS estimated using generalized boosted models (IPTW-
GBM); 3) IPTW-MLR with trimmed weights; 4) IPTW-GBM with trimmed weights; 5) RAMS with GPS
estimated using multinomial logistic regression (RAMS-MLR); 6) RAMS with GPSs estimated using the
generalized boosted models (RAMS-GBM); 7) RAMS-MLR with trimmed GPSs (RAMS-MLR-Trim); 8)
RAMS-GBM with trimmed GPSs (RAMS-GBM-Trim); and 9) BART.
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3.1.2 Simulation II: Outcome prevalence
We further compared the nine methods vetted in the first simulation with respect to another design factor:
the outcome prevalence. We varied the outcome prevalence in each of three treatment groups in two scenarios:
1) 1%−5% (extremely rare), and 2) 5%−10% (rare). That is, we simulated the outcomes with the prevalence
rate falling within the range 1-5% and 5-10%, respectively. We generated data sets following the simulation
configuration of scenario 3 in Simulation I, that is, N = 9, 500 and n1 : n2 : n3 = 1 : 10 : 8. The model
specification of the treatment assignment mechanism is the same as in Simulation I and τw’s in the response
surfaces were modified to vary the outcome prevalence.
3.1.3 Simulation III: Covariate overlap
We finally investigated how levels of covariate overlap impact causal estimates with multiple treatments and
rare outcomes. We generated data sets using the simulation configuration of scenario 3 in Simulation I and
of scenario 1 in Simulation II, including the total sample size, the ratio of units, the outcome prevalence, the
number of continuous and categorical confounders, and the response surface models, to mimic the SEER-
Medicare dataset, but varied the treatment assignment models (12) to create shifting degrees of covariate
overlap.
We considered three levels of covariate overlap: 1) strong - there was strong overlap with respect to each
of the 10 confounders; 2) moderate - the five categorical variables had sufficient overlap as in the strong
scenario but there were lack of overlap in the five continuous variables ; and 3) weak - there was lack of
overlap in the covariate space defined by all 10 confounders. In all scenarios, the lack of overlap was induced in
true confounders, i.e., variables included in both the treatment assignment model and the response surfaces.
This simulation was designed to make it difficult for any method to successfully estimate the true treatment
effects, as both the treatment assignment and the outcome are difficult to model.
We first generated the treatment variable W from a multinomial distribution, W ∼ Multinomial (9500,
.05, .53, .42), and then generated each covariate from their respective distributions conditional on treatment
assignment to create varying levels of covariate overlap. In the strong scenario overlap, we created strong
covariate overlap by generating similar distributions of the covariates across the treatment groups for all
10 confounders. Specifically, we assumed that the five continuous variables follow the normal distribution
Xij |Wi ∼ N (0, 1−0.01Wi) for j = 1, . . . , 5, and the five categorical variables follow multinomial distribution
Xij |Wi ∼ Multinomial(N, 0.3, 0.3, 0.4) for j = 6, . . . , 10. In the moderate overlap scenario, we assumed
that the five continuous variables follow the normal distribution Xij |Wi ∼ N (0.05Wi, 1 − 0.05Wi) for j =
1, . . . , 5, and the five categorical variables follow the multinomial distribution Xij |Wi ∼ Multinomial(N, 0.3−
0.01Wi, 0.3 + 0.01Wi, 0.4) for j = 6, . . . , 10. In the weak scenario overlap, we created the lack of overlap for
five continuous variables. We assumed that Xij |Wi = 1 ∼ N (−0.5, 1), Xij |Wi = 2 ∼ N (1, 1), Xij |Wi = 3 ∼
N (2, 1) for j = 1, . . . , 5, and Xij |Wi ∼ Multinomial(N, 0.3− 0.001Wi, 0.3 + 0.001Wi, 0.4), for j = 6, . . . , 10.
Boxplots of distributions of estimated GPSs across the treatments were used to visualize the degree of
covariate overlap, see Figure S1 in Supplemental Materials. We used the BART discarding strategy in (9) to
assess whether this strategy (BART-Discard) improved over BART.
For all three simulations described above, we evaluated the performance of all methods considered using
the ATE estimates based on marginal RD. True treatment effects were computed based on a simulated
population of size 100,000. For each method, in each of 200 replications of each scenario, we estimated
three pairwise ATEs, ATE1,2, ATE1,3 and ATE2,3, and the bias in each estimate. Using these values, we
calculated for each method and each scenario, the mean absolute bias (MAB) and the root mean square
error (RMSE). The Monte Carlo simulation error (MCSE) was also provided to show the variability across
simulation replications. The number of events and outcome prevalence rates in each of treatment groups for
each of simulation scenarios are summarized in Table S4 in Supplemental Materials.
We implemented the methods as follows. The GPSs were estimated using both multinomial logistic
regression model (MLR) and GBM. GBM was implemented using the mnps() function available in the
twang package in R. The The stopping rule for the optimal iteration of the generalized boosted model was
based on maximum of absolute standardized bias, which compares the distributions of the covariates between
treatment groups (McCaffrey et al., 2013). RAMS was implemented using the gam() function with tensor
product smoother te() in the gam package in R. The weights or the GPSs were trimmed at 5% and 95%
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to generate trimmed estimators for IPTW and RAMS, respectively. For BART, we used the default priors
associated with the bart() function available in the BART package in R. For each BART fit, we allowed the
maximum number of trees in the sum to be 100. To ensure the convergence of the MCMC in BART, we let
the algorithm run for 5000 iterations with the first 3000 considered as burn-in.
3.2 Simulation Results
3.2.1 Simulation I
Table 2 displays the MAB and RMSE of the estimates of three ATE effects ATE1,2,ATE1,3 and ATE2,3
for the three scenarios in Simulation I. BART consistently yielded the lowest MAB and RMSE across all
three scenarios with different ratio of units and varying sample sizes, and for all pairwise treatment effects.
The second best method is RAMS, judged by both MAB and RMSE. Implementation of the GBM for
estimating the GPSs only moderately improved the performance of RAMS over the use of MLR. The flexible
spline function of the GPSs in RAMS may lessen the need for GPS model accuracy. IPTW based methods
produced large MAB and RMSE, with IPTW-MLR giving the largest bias and variability. Trimming appeared
to improve the performance of IPTW-MLR but had negligible effect on IPTW-GBM and RAMS. BART
was not sensitive to the ratio of units or sample size, whereas the GPS methods tended to have better
performance as the sample sizes in the comparison treatment groups grew relative to the reference treatment
group.
Table 2: Comparisons of the estimated average treatment effects (ATE) in terms of mean absolute bias
(MAB) and root mean square error (RMSE) across 200 replications in Simulation I. The causal estimand is
based on percent risk difference, i.e., (risk difference between treatment groups)×100. MSCE: Monte Carlo
simulation error, calculated as standard deviation of bias/
√
200. In Scenario 1), the true ATE1,2 = 0.88%,
ATE1,3 = 0.70%, ATE2,3 = 0.92%. In Scenario 2), the true ATE1,2 = 0.86%, ATE1,3 = 0.74%, ATE2,3 =
0.98%. In Scenario 3), the true ATE1,2 = 0.82%,ATE1,3 = 0.74%, ATE2,3 = 0.94%.
ATE1,2 ATE1,3 ATE2,3
Scenario Method MAB RMSE MCSE MAB RMSE MCSE MAB RMSE MCSE
IPTW-MLR 3.10 3.44 0.24 2.91 3.31 0.23 2.92 3.31 0.23
IPTW-MLR-Trim 2.46 2.81 0.20 2.53 2.80 0.20 2.51 2.80 0.20
IPTW-GBM 2.14 2.47 0.17 1.93 2.21 0.16 2.09 2.21 0.16
IPTW-GBM-Trim 1.95 2.22 0.16 1.92 2.18 0.15 1.86 2.18 0.15
1) n = 1500 BART 1.02 1.15 0.08 0.80 0.92 0.06 0.88 0.92 0.06
Ratio of units = 1:1:1 RAMS-MLR 1.62 1.81 0.12 1.44 1.61 0.11 1.45 1.61 0.11
RAMS-MLR-Trim 1.52 1.69 0.12 1.35 1.52 0.11 1.42 1.52 0.11
RAMS-GBM 1.57 1.76 0.12 1.33 1.51 0.11 1.46 1.51 0.11
RAMS-GBM-Trim 1.46 1.72 0.12 1.25 1.43 0.10 1.40 1.43 0.10
IPTW-MLR 2.44 2.74 0.19 2.49 2.80 0.20 2.63 2.80 0.20
IPTW-MLR-Trim 2.07 2.32 0.16 1.95 2.19 0.15 2.02 2.19 0.15
IPTW-GBM 1.50 1.70 0.12 1.50 1.70 0.12 1.53 1.70 0.12
IPTW-GBM-Trim 1.57 1.77 0.12 1.40 1.58 0.11 1.29 1.58 0.11
2) n = 4000 BART 0.89 0.99 0.07 0.89 1.01 0.07 1.00 1.01 0.07
Ratio of units = 1:4:3 RAMS-MLR 1.25 1.43 0.10 1.22 1.37 0.10 1.17 1.37 0.10
RAMS-MLR-Trim 1.17 1.33 0.09 1.29 1.45 0.10 1.15 1.45 0.10
RAMS-GBM 1.35 1.50 0.11 1.16 1.31 0.09 1.20 1.31 0.09
RAMS-GBM-Trim 1.18 1.35 0.09 1.19 1.34 0.09 1.33 1.34 0.09
IPTW-MLR 2.04 2.27 0.16 1.99 2.17 0.15 1.98 2.17 0.15
IPTW-MLR-Trim 1.75 1.98 0.14 1.95 2.14 0.15 1.77 2.14 0.15
IPTW-GBM 1.35 1.51 0.10 1.36 1.53 0.11 1.36 1.53 0.11
IPTW-GBM-Trim 1.25 1.41 0.10 1.21 1.35 0.09 1.24 1.35 0.09
3) n = 9500 BART 0.90 1.03 0.07 0.82 0.90 0.06 0.74 0.90 0.06
Ratio of units = 1:10:8 RAMS-MLR 1.14 1.26 0.09 1.05 1.20 0.08 1.04 1.20 0.08
RAMS-MLR-Trim 1.11 1.27 0.09 1.02 1.17 0.08 0.95 1.17 0.08
RAMS-GBM 1.09 1.23 0.09 0.94 1.08 0.07 1.00 1.08 0.07
RAMS-GBM-Trim 1.09 1.23 0.09 0.95 1.09 0.08 1.03 1.09 0.08
3.2.2 Simulation II
Figure 1 displays boxplots of biases of three treatment effects ATE1,2, ATE1,3 and ATE2,3 among 200 simu-
lations for each of the nine methods and two outcome prevalence rates of 1%–5% and 5%–10% in Simulation
Estimation of causal effects of multiple treatments in healthcare database studies with rare outcomes 11
Fig. 1: Biases among 200 replications under two outcome prevalence rates of 1–5% and 5–10% for each of
nine methods and three ATE effects ATE1,2, ATE1,3 and ATE2,3 based on percent risk difference, i.e.,
(risk difference between treatment groups)×100. For prevalence rate of 1–5%, the true ATE1,2 = 0.73%,
ATE1,3 = 1.17%, ATE2,3 = 1.21%. For prevalence rate of 5–10%, the true ATE1,2 = 1.26%, ATE1,3 =
0.72%, ATE2,3 = 0.98%.
II. As in Simulation I, BART boasted the smallest bias and variability among the nine methods for both
outcome prevalence rates across all three treatment effects. RAMS, following BART, delivered considerably
better performance than IPTW based methods, for having both smaller bias and higher precision. Using
GBM to estimate the GPSs for RAMS led to only a moderate bias reduction compared to using MLR,
with slightly better improvement when the outcome prevalence was lower. Trimming again improved only
IPTW-MLR but did not have a noticeable impact on GBM and RAMS. The advantage of BART over
RAMS diminished when the outcome prevalence increased and RAMS achieved better bias reduction and
precision. IPTW based methods also had better performance under higher outcome prevalence. Table S2 in
Supplemental Materials compares the MAB and RMSE of each method under two outcome prevalence rates.
3.2.3 Simulation III
Figure 2 compares biases of three treatment effect estimators ATE1,2, ATE1,3 and ATE2,3 among 200
simulations under three levels of covariate overlap for each of RAMS-MLR, RAMS-MLR-Trim, RAMS-GBM,
RAMS-GBM-Trim, BART and BART with discarding rules.
BART demonstrated smaller bias and variability than RAMS across all three levels of covariate overlap.
The difference is less evident in the scenario of weak covariate overlap than in the scenarios of moderate
and strong overlap. The BART discarding rule considerably reduced the biases in the estimates of the ATE
effects in the weak scenario where there was substantial lack of covariate overlap. When there was a strong
or moderate covariate overlap, BART with and without discarding performed equally well. BART discarding
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Fig. 2: Biases among 200 replications under varying level of covariate overlap for BART vs. RAMS and three
treatment effects ATE1,2, ATE1,3 and ATE2,3. The causal estimand is the marginal percent risk difference
between treatment groups, i.e., (risk difference between treatment groups) ×100. For weak overlap, the true
ATE1,2 = 1.25%, ATE1,3 = 0.77%, ATE2,3 = 0.88%. For moderate overlap, the true ATE1,2 = 0.97%,
ATE1,3 = 0.89%, ATE2,3 = 1.16%. For strong overlap, the true ATE1,2 = 0.97%, ATE1,3 = 0.73%,
ATE2,3 = 1.40%.
strategy excluded 7.1% , 0.2% and 0% units on average across 200 replications for the weak, moderate and
strong overlap, respectively. Flexibility in estimating the GPSs using the GBM improved the performance
of RAMS when the covaraite overlap was weak or moderate. Trimming improved RAMS-MLR under weak
overlap, and gave similar results when the covariate overlap was strong or moderate. Table S3 in Supplemental
Materials shows the MAB and RMSE of each method under different levels of covariate overlap.
4 Real data analysis
As mentioned in Section 1.3, in this paper we compared the effectiveness of the three surgical procedures,
RAS, VATS and OT, on the following four postoperative outcomes: the presence of (i) extra-pulmonary
infection; (ii) cardiovascular complication; (iii) thromboembolic complication; and (iv) reoperation within 30
days of surgery or during the hospitalization in which the primary surgical procedure was performed.
We estimated three pairwise ATEs in terms of marginal RD between the three surgical procedures in
the overall population using the methods examined in the simulations. IPTW-MLR was not included in the
real data application due to its relatively poor performance shown in the simulations. In addition, trimming
method was not considered for RAMS because the impact of trimming on the GPS for RAMS was shown to
be trivial. Results from BART-Discard were not shown as they were the same as the estimates of BART (no
units were discarded). An assessment of covariate overlap shows that the baseline characteristics has relatively
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strong overlap; see Figure S2 in Supplemental Materials. Confidence intervals of ATEs were estimated using
nonparametric bootstrap for IPTW and RAMS, and Bayesian posterior credible intervals were estimated for
BART. All of the methods were implemented as described in the simulation studies.
Table 3 presents the point and interval estimates of the ATEs for RAS versus OT, RAS versus VATS and
OT versus VATS, in terms of marginal RD. All of the methods yielded statistically insignificant treatment
effects on the four outcomes for RAS versus OT or VATS, suggesting that RAS did not have a significant
advantage over VATS or OT on postoperative complications. Results from different methods consistently
showed lower rates of post-operative extrapulmonary infection and reoperation among patients treated with
VATS compared to OT. Of the four methods, BART provided the narrowest uncertainty intervals, whereas
IPTW produced the largest width of confidence intervals. Results from this comparative effectiveness study
provided partial evidence that VATS may lead to lower rates of post-operative reoperation and extrapul-
monary infection compared to OT, and that RAS has no evident advantage over VATS or OT.
Table 3: Estimated ATE1,2, ATE1,3 and ATE2,3 (95% uncertainty intervals in parentheses) of three surgical procedures on
postoperative rare outcomes. The causal estimand is the marginal percent risk difference, i.e., (risk difference between treatment
groups) * 100.
RAS vs. OT RAS vs. VATS OT vs. VATS
Outcomes Methods Estimate 95% CI Estimate 95% CI Estimate 95% CI
IPTW-GBM -2.9 (-5.5,3.0) -0.6 (-3.2,2.3) 2.3 (0.7,3.8)
Extrapulmonary BART -2.1 (-3.2,0.4) -0.4 (-1.8,1.0) 1.7 (1.0,2.4)
infection RAMS-MLR -2.7 (-4.3,0.6) -0.7 (-2.3,1.3) 1.9 (0.7,3.5)
RAMS-GBM -2.9 (-4.5,0.9) -0.7 (-2.2,1.3) 2.3 (1.6,3.6)
IPTW-GBM 0.1 (-1.9,5.7) 0.6 (-1.3,6.6) 0.5 (-0.8,1.8)
Cardiovascular BART 0.1 (-1.0,1.4) 0.2 (-0.5,1.0) 0.2 (-0.1,0.6)
complication RAMS-MLR 0.5 (-1.1,2.2) 0.8 (-0.8,2.4) 0.3 (-0.2,1.0)
RAMS-GBM 0.1 (-1.3,1.6) 0.5 (-0.9,2.0) 0.4 (-0.1,1.0)
IPTW-GBM 0.7 (-2.5,6.4) 0.6 (-2.8,5.9) -0.1 (-2.1,1.5)
Thromboembolic BART 0.6 (-1.3,2.6) 0.5 (-1.2,2.3) 0.0 (-0.5,0.5)
complication RAMS-MLR 0.8 (-1.7,3.3) 0.9 (-1.5,3.4) 0.1 (-0.7,0.9)
RAMS-GBM 0.7 (-1.5,3.1) 0.6 (-1.7,3.0) -0.1 (-1.0,0.7)
IPTW-GBM -0.3 (-1.6,3.2) 0.4 (-0.9,3.4) 0.7 (0.1,1.3)
Reoperation BART -0.3 (-1.1,0.9) 0.3 (-0.3,0.9) 0.5 (0.3,0.7)
RAMS-MLR -0.3 (-1.3,1.0) 0.5 (-0.5,1.7) 0.8 (0.4,1.2)
RAMS-GBM -0.3 (-1.2,1.0) 0.5 (-0.4,1.7) 0.8 (0.4,1.1)
We performed a sensitivity analysis to evaluate the impact of the choice of hyperparameter in the end-node
piror for BART, that is, the choice of k in the bart() function (Dorie et al., 2016). Five-fold cross-validation
was used to select the optimal hyperparameter k that minimized the misclassification error. Results suggest
that BART with the optional k gave similar point and interval estimates of the ATEs as BART with the
default value of k (not shown). Furthermore, we implemented our BART-specific discarding rule for ATEs
(9) to identify if there are any units that lack common support and thus should be discarded to avoid
inference for them. We did not exclude any such patients from the real data set. We conducted an empirical
investigation to examine whether the dimensions of the GPSs for the bivariate spline function of the RAMS
method impact the estimation of the causal effects. Table S5 shows that the estimated ATEs did not change
with different dimensions of the GPSs.
5 Discussion
The primary contribution of this paper to the causal inference literature is the proposal and extension of sev-
eral methods to the multiple treatments and rare outcome setting. The advent of large-scale population-based
healthcare database brings analytic challenges and demands novel methodology beyond traditional causal
inference techniques. Causal inference methods have been predominantly focusing on a binary treatment,
and research for handling multiple treatments especially when the outcome is a rare event is sparse. Previous
studies have provided extensive empirical evidence for the comparison of a variety of causal inference methods
in either the multiple treatment setting (Hu et al., 2020) or the rare outcome setting (Franklin et al., 2017),
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but not both. In the multiple treatments setting, Hu et al. (2020) explicated that BART gives lower bias,
smaller RMSE, more coherent uncertainty intervals and better convergence property than other methods
examined. Franklin et al. (2017) demonstrated that regression on the PS using a spline function produces
smaller bias and lower standard errors than other PS-based methods in the context of rare outcomes.
We extended both BART and regression adjustment with PS using spline to the multiple treatment setting
when the outcome is binary with low prevalence, and compared them with the commonly used IPTW-based
methods. We conducted three unique sets of simulations that represented complex causal inference settings
motivated by the structure of the SEER-Medicare data.
BART consistently produced better performance in terms of bias and RMSE for pairwise ATEs across all
scenarios regarding ratio of units, outcome prevalence and covariate overlap. RAMS, using a multidimensional
spline of GPS, trailed BART but outperformed all IPTW-based methods including the machine learning
based IPTW-GBM. The performance of RAMS was generally improved when more flexible models were
used to estimate the GPS. The advantage of BART over RAMS was reduced and both methods delivered
good performance when the outcome prevalence was relatively higher (5%–10%) or when there was sufficient
covariate overlap. When there is a substantial amount of lack of overlap in the covariate space, the BART-
specific discarding rule markedly improved over plain BART.
RAMS-MLR is the most computationally efficient method while IPTW-GBM is the least. On a dataset of
size n = 9500, one RAMS-MLR implemention takes less than 5 seconds to run and one BART implementation
takes less than 150 seconds on a iMAC with a 4GHz Intel Core i7 processor. In a stark comparison, one IPTW-
GBM implementation takes about 10 minutes to generate results. Considering the easy implementation and
computational efficiency, RAMS may be recommended in the settings where the covariate overlap is strong
or the outcome prevalence is relatively high.
We implemented methods examined on 11980 stage I-IIIA NSCLC patients, drawn from the latest SEER-
Medicare linkage. Results suggest that VATS may be preferred over OT in terms of extrapulmonary infection
and reoperation in the general population. There is no evidence showing that RAS leads to better post-
operative outcomes compared to OT or VATS. Given that RAS was associated with significantly higher
costs, specifically those incurred in the pre-operative period compared to VATS (Veluswamy et al., 2019),
RAS therefore may not be a cost-effective option in routine care for the surgical management of patients
with NSCLC.
Our work provides several important avenues for future research in the multiple treatments and rare
outcome setting. First, the flexibility offered by the nonparametric modeling of BART can be leveraged
to model nonlinear regression relationship in time to event data. Second, individual treatment effects and
coherent uncertainty intervals can be easily obtained from the BART model, which provides a building
block for assessing heterogeneous treatment effect and identify subgroups for optimal treatment. Third, the
proposed RAMS assumes that the treatment variable and spline function of the GPS are included into
the model additively. This model formulation may not provide a valid treatment effect estimate in the
presence of treatment effect heterogeneity because it ignores potential interaction between the treatment
variable and the spline function of the GPS. Gutman and Rubin (2013) proposed a multiple imputation
with two splines and subclassification method (MITSS) for a binary treatment, which can correctly model
the association between the outcome and the PS even in the presence of strong treatment heterogeneity.
Further development of RAMS for estimating heterogeneous treatment effects is a future direction. Finally,
we have made a significant untestable assumption related to unmeasured confounding. Developing sensitivity
analyses under the complex multiple treatment and rare outcome setting leveraging BART would also be a
worthwhile and important contribution.
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